title: Autoimmune thrombocytopenic purpura during pegylated interferon α treatment for chronic hepatitis C.
abstract: We describe a 72-year-old woman with chronic hepatitis C and autoimmune thrombocytopenic purpura (AITP) during pegylated interferon (PEG-IFN) alpha. Immunoglobulin G and antinuclear antibody were 2,113 mg/dL and 1,280 at the start, respectively. A liver biopsy negated autoimmune hepatitis. After a 48-week combination therapy with ribavirin, PEG-IFN alpha-2a was administered. At the 30th month, the platelet count was decreased to 1.1 x 10(4)/microL. Bone marrow biopsy disclosed normocellular marrow compatible with AITP. The platelet-associated IgG (PAIgG) titer rose to 500 ng/10(7) cells. Corticosteroid therapy was successful, and the platelet count and PAIgG titer reverted to 6.4 x 10(4)/microL and 57.3 ng/10(7) cells, respectively.
authors.affiliation: Department of Gastroenterology, Kobe Asahi Hospital, Kobe, Japan.
authors.forename: Soo Ryang
authors.initials: SR
authors.lastname: Kim
authors.forename: Susumu
authors.initials: S
authors.lastname: Imoto
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
authors.forename: Taisuke
authors.initials: T
authors.lastname: Nakajima
authors.forename: Kenji
authors.initials: K
authors.lastname: Ando
authors.forename: Keiji
authors.initials: K
authors.lastname: Mita
authors.forename: Katsumi
authors.initials: K
authors.lastname: Fukuda
authors.forename: Hyun Soo
authors.initials: HS
authors.lastname: Hong
authors.forename: Yeong Ho
authors.initials: YH
authors.lastname: Lee
authors.forename: Keiichi
authors.initials: K
authors.lastname: Nakashima
authors.forename: Ikuo
authors.initials: I
authors.lastname: Shoji
authors.forename: Motoko
authors.initials: M
authors.lastname: Nagano-Fujii
authors.forename: Hak
authors.initials: H
authors.lastname: Hotta
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000368:Aged; D004337:Drug Carriers; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D004337:Drug Carriers; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a